These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12200028)

  • 1. Age-associated biomarker profiles of human breast cancer.
    Eppenberger-Castori S; Moore DH; Thor AD; Edgerton SM; Kueng W; Eppenberger U; Benz CC
    Int J Biochem Cell Biol; 2002 Nov; 34(11):1318-30. PubMed ID: 12200028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of uPA, PAI-1, cathepsin D and apoptotic cells in ductal carcinoma in situ of the breast.
    Zhao H; Morimoto T; Sasa M; Tanaka T; Izumi K
    Breast Cancer; 2002; 9(2):118-26. PubMed ID: 12016391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.
    Gasparini G; Toi M; Biganzoli E; Dittadi R; Fanelli M; Morabito A; Boracchi P; Gion M
    Oncology; 2001; 60(1):72-80. PubMed ID: 11150912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
    Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
    Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
    Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-dependent changes in breast cancer hormone receptors and oxidant stress markers.
    Quong J; Eppenberger-Castori S; Moore D; Scott GK; Birrer MJ; Kueng W; Eppenberger U; Benz CC
    Breast Cancer Res Treat; 2002 Dec; 76(3):221-36. PubMed ID: 12462383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
    Eppenberger U; Kueng W; Schlaeppi JM; Roesel JL; Benz C; Mueller H; Matter A; Zuber M; Luescher K; Litschgi M; Schmitt M; Foekens JA; Eppenberger-Castori S
    J Clin Oncol; 1998 Sep; 16(9):3129-36. PubMed ID: 9738585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
    Harbeck N; Thomssen C; Berger U; Ulm K; Kates RE; Höfler H; Jänicke F; Graeff H; Schmitt M
    Breast Cancer Res Treat; 1999 Mar; 54(2):147-57. PubMed ID: 10424405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of epidermal growth factor receptor (EGFR) in hormone-independent breast cancers].
    Ruibal A; Garrido-Pumar M; Arias JI
    Rev Esp Med Nucl; 2006; 25(1):15-9. PubMed ID: 16540006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
    Garimella V; Hussain T; Agarwal V; Radhakrishna S; Fox JN; Kneeshaw PJ; Long ED; Mahapatra TK; McManus PL; Lind MJ; Drew PJ; Cawkwell L
    Int J Surg; 2014; 12(8):821-6. PubMed ID: 25010604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation.
    Nakopoulou L; Stefanaki K; Panayotopoulou E; Giannopoulou I; Athanassiadou P; Gakiopoulou-Givalou H; Louvrou A
    Hum Pathol; 2002 Sep; 33(9):863-70. PubMed ID: 12378509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
    Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
    Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can axillary dissection be avoided by improved molecular biological diagnosis?
    Lindahl T; Engel G; Ahlgren J; Klaar S; Bjöhle J; Lindman H; Andersson J; von Schoultz E; Bergh J
    Acta Oncol; 2000; 39(3):319-26. PubMed ID: 10987228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors.
    González-Vela MC; Garijo MF; Fernández F; Val-Bernal JF
    Histol Histopathol; 2001 Apr; 16(2):399-406. PubMed ID: 11332695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.